Treatment of erectile dysfunction

International Journal of STD and AIDS

Volumn 15, Issue 4, 2004, Pages 215-221

  Dinsmore, Wallace ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Alprostadil; Erectile dysfunction; Papaverine; Phentolamine; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; NITRO DERIVATIVE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERANCE; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; META ANALYSIS; MYALGIA; PENIS ERECTION; PENIS PROSTHESIS; PRIAPISM; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RHINITIS; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SINUSITIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASOCONSTRICTION; VISUAL IMPAIRMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; CARBOLINES; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TRIAZINES; VACUUM; VASODILATOR AGENTS;

EID: 2342629916     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646204773557721     Document Type: Review

References (60)

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the First International Consultation on Erectile Dysfunction, co-sponsored by the World Health Organisation. Plymouth: Health Publications Ltd, 2000
2. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
4. Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement update - 2002. Int J Clin Pract 2002;56:663-71
5. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6
6. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90
7. Vitezic D, Pelcic JM. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther 2002;40:393-403
8. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8
9. Meuleman EJ, Donkers LH, Robertson C, et al. [Erectile dysfunction: prevalence and effect on the quality of life; Boxmeer study]. Ned Tijdschr Geneeskd 2001;145:576-81
10. Nicolosi A, Classer DB, Moreira ED, Villa M. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003;15:253-7
11. Montorsi F, Salonia A, Montorsi P. May erectile dysfunction predict ischaemic heart disease? J Urol 2002;167 (Suppl):148 (abstract 591)
12. Jackson G. Erectile dysfunction and hypertension. Int J Clin Pract 2002;56:491, 3
13. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164:1188-91
14. De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 2002;25:284-91
15. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002;14:466-71
16. Chamssuddin A, Al-Om M, Ramadan S. Management of erectile function in diabetic patients. Progres en Urologie 2003;12 (Suppl 2):1 (Abstract)
17. Tan RS, Pu SJ. The interlinked depression, erectile dysfunction, and coronary heart disease syndrome in older men: a triad often under diagnosed. J Gend Specif Med 2003;6:31-6
18. Pagani M. Hypertension, stress and erectile dysfunction: potential insights from the analysis of heart rate variability. Curr Med Res Opin 2000;16 (Suppl 1):s3-8
19. Schrooten W, Colebunders R, Youle M, et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment AIDS 2001;15:1019-23
20. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res 2001;13 (Suppl 3):S8-S17
21. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther 2001;296:225-34
22. Traish A, Kim NN, Moreland RB, Goldstein II. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000;12:S48-63
23. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001;67:257-63
24. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9
25. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-90
26. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82
27. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36:25-31
28. Rosen RC, McKenna KE. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 2002;13:36-88
29. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001;65:1-52
30. Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011-18
31. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002;60:67-90
32. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6
33. Pfizer Limited. Viagra Summary of Product Characteristics, 2003
34. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53 (Suppl 1):5S-12S
35. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404
36. Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999;53:800-5
37. Gingell C, Buvat J, Jardin A, et al. Sildenafil citrate (VIAGRA), an oral treatment for erectile function: 1-year, open-label, extension studies. Multicentre Study Group. Int J Clin Pract Suppl 1999;102:30-1
38. Moore R, Edwards J, McQuay H. Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2002;2:6
39. Olsson AM, Persson CA. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001;55:171-6
40. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001;14:70-3
41. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002;60:12-27
42. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84
43. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998;51:1629-33
44. Maytom MC, Derry FA, Dinsmore WW, et al. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999;37:110-16
45. Bayer plc. Levitra Summary of Product Characteristics. 2003
46. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001;40:181-8; discussion 9-90
47. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003;43:260-7
48. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9
49. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71
50. Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003;61:8-14
51. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
52. Eli Lilly and Company Limited. Cialis Summary of Product Characteristics, 2003
53. Patterson D, Bedding A, Jewell H, Payne C, Mitchell MI. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). 4th Congress of the European Society for Sexual and Impotence Research, 2001; Rome, Italy
54. Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2-9
55. Padma-Nathan H, Brock G, McMahon C, et al. Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. 17th Annual Scientific Meeting of the American Society of Hypertension (ASH). New York, NY, USA, 2002.
56. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64
57. Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:887-91
58. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159:1541-7
59. Giuliano F. Introduction: advances in the treatment of erectile dysfunction. Eur Urol Suppl 2002;1:1-3
60. Brock GB, Bochinski D. Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. Curr Opin Urol 2001;11:625-30